Diagnosing Sepsis Early and Saving Lives: An Interview with Cytovale
Comments on the theory, methods, and potential of the sepsis-detecting Cytovale System from Cytovale CEO and co-founder, Ajay Shah, Ph.D.
BTK Inhibitor Rilzabrutinib Shows Efficacy in Immune Thrombocytopenia
Preliminary data from a phase 1/2 trial indicate that Principia Biopharma’s BTK inhibitor Rilzabrutinib could treat immune thrombocytopenia.
Dendritic Cell Activation Found to Boost Efficacy of T Cell Immunotherapies
Australian researchers found that T cells engineered to express the dendritic cell growth factor Flt3L overcame an important obstacle to the treatment of solid tumors.
Germinal Center Reaction Found to be Orchestrated by Distinct FDC Niches
Swiss scientists have found that the function of follicular dendritic cells within germinal centers is influenced by their spatial position.
Regulatory T Cells Found to Promote the Development of CD8+ TRM T Cells
Portuguese researchers discovered that type 1 regulatory T cells increase the availability of TGF-beta to promote CD8+ TRM T cell generation.
KIT Inhibitor CDX-0159 Shows Potential As Therapy for Mast Cell Diseases
Celldex Therapeutics’ CDX-0159, an inhibitor of the KIT receptor, led to sustained reductions in plasma tryptase levels in the phase 1 trial.
Researchers Profile Immune Cells Implicated in Neurodegenerative Diseases
The team of Dr. Katerina Akassoglou at Gladstone Institutes and UCSF studied the gene signature of pathogenic innate immune cells in the CNS.
BTK Inhibitor Acalabrutinib Supports Patients with Severe Cases of COVID-19
Calquence (Acalabrutinib), Astrazeneca’s bruton tyrosine kinase inhibitor, is thought to treat COVID-19 by suppressing lung macrophages.
JAK1 Inhibitor Filgotinib Shows Efficacy in Treatment of Psoriatic Arthritis
Gilead and Galapagos NV announced the results of two phase 2 human trials evaluating filgotinib in adults with psoriatic arthritis.
Jounce Regains Worldwide Rights to LILRB2 Inhibitor JTX-8064 from BMS
Rights to the antibody candidate JTX-8064 have been transferred from Bristol-Myers Squibb back to Jounce Therapeutics effective June 3rd 2020.